BIRC5 and ovarian carcinoma: Several studies have shown miR‐302 inhibits proliferation and acts as a tumour suppressor in a variety of cancers,26, 27, 28 including ovarian cancer.29 MiR‐302e was transfected into ovarian cancer cells CAOV3 and A2780, and the expression of VEGFA, TGF‐α and survivin was down‐regulated compared with the control group, suggesting the inhibitory effect of miR‐302e on the occurrence and development of ovarian cancer.